Prot#ING111762: A Phase III Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 50 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Both Administered with an Investigator Selected Background Regimen Over 48 Weeks in HIV-1 Infected,

Project: Research project

Project Details

StatusFinished
Effective start/end date2/1/11 → 2/1/14

Funding

  • GlaxoSmithKline plc (ING111762 // ING111762)
  • ViiV Healthcare (ING111762 // ING111762)